Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: vitamin D

Rheumatology Drug Updates: Opana ER Painkiller Pulled from U.S. Market; Upadacitinib to Treat RA, and More

Michele B. Kaufman, PharmD, BCGP  |  August 13, 2017

Opana ER Pulled from U.S. Market Last month, the U.S. Food and Drug Administration (FDA) asked Endo Pharmaceuticals to remove oxymorphone hydrochloride extended release (Opana ER) from the U.S. market due to public health consequences related to abuse. The agency has concerns that the risks presented by the treatment do not outweigh its benefits.1 On…

Filed under:Drug UpdatesResearch Rheum Tagged with:abataceptabuseAddictionApprovalsClinicalDrugsEndo PharmaceuticalsFDAMedicationOpana ERopioidoxymorphone hydrochloride extended releasepainkillerResearchresultsSafetytopical diclofenac sodiumtrialupadacitinib

Novel Bone Drug Promising in Postmenopausal Osteoporosis

Reuters Staff  |  August 7, 2017

NEW YORK (Reuters Health)—The investigational drug romosozumab led to gains in hip bone mineral density (BMD) that were not seen with teriparatide in older women with osteoporosis transitioning from bisphosphonate therapy in the STRUCTURE study. Amgen’s romosozumab is a monoclonal antibody that inhibits sclerosin, a negative regulator of bone formation. In addition to stimulating bone…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)Osteoporosisosteoporosis treatmentspostmenopauseromosozumab

Mind-Body Techniques for Pain Management

Lara C. Pullen, PhD  |  July 14, 2017

CHICAGO—Delia Chiaramonte, MD, associate director of education at the Center for Integrative Medicine at the University of Maryland School of Medicine in Baltimore, presented the newest thinking on pain to a gathering of rheumatologists at the ACR’s State-of-the-Art Clinical Symposium in April. She began by explaining that pain is more than nociception. Nociception stimulates nerves to…

Filed under:ConditionsMeeting ReportsPain SyndromesResearch Rheum Tagged with:2017 State of the Art Clinical SymposiumAC&RAmerican College of Rheumatology (ACR)braincentral nervous systemFibromyalgiameditationmindPain ManagementResearchrheumatologyyoga

News Updates for Diclofenac Sodium, Denosumab & Sarilumab

Michele B. Kaufman, PharmD, BCGP  |  June 20, 2017

In drug news, a generic 2% diclofenac sodium solution is now available, denosumab is promising to treat osteoporosis, and the FDA has approved sarilumab to treat adults with RA…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:denosumabdiclofenac sodiumFDAFood and Drug Administrationgeneric drugsKnee Osteoarthritis (OA)OsteoporosisRheumatoid Arthritis (RA)sarilumab

More Effective Antifibrotic Therapies for Systemic Sclerosis in Development; Adverse Events A Concern

Susan Bernstein  |  June 14, 2017

Systemic sclerosis (SSc) is a rare disease affecting about 49,000 U.S. adults, and it is strongly associated with high levels of morbidity and mortality.1 Of the few available antifibrotic therapies, none is targeted for SSc. However, reason for optimism exists for antifibrotic treatments in early development and clinical trials, says Jörg H.W. Distler, MD, Heisenberg Professor…

Filed under:ConditionsResearch RheumSystemic Sclerosis Tagged with:adverse eventsantifibrotic therapyClinicaloutcomepatient careResearchrheumatologistrheumatologySclerodermaSystemic sclerosisTreatment

Infliximab-abda Becomes 5th Biosimilar Approved in the U.S. & Abaloparatide Approved for Osteoporosis

Michele B. Kaufman, PharmD, BCGP  |  May 22, 2017

The FDA has approved infliximab-abda, a biosimilar for treating multiple rheumatic diseases, as well as abaloparatide for treating postmenopausal women with osteoporosis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:abaloparatideFDAFood and Drug Administrationinfliximabinfliximab-abdaOsteoporosis

Weakness, Fatigue Can Signal Underlying Rheumatologic Disease

Simon M. Helfgott, MD  |  April 17, 2017

As clinicians, we are familiar with pain, stiffness and soreness—subjective nouns that define our métier. These helpful words serve as signposts that direct us along the path to the proper diagnosis. Consider the young man with a stiff, sore back (a case of ankylosing spondylitis?) or the postpartum woman experiencing newly painful, stiff and sore…

Filed under:ConditionsOpinionRheuminationsSpeak Out Rheum Tagged with:Diagnosisfatigueillnessinflammatory myositisLupusMyopathyOsteoarthritisoutcomepatient careRheumatic DiseaserheumatologistthyroidTreatmentweakness

Monkey Business Images/shutterstock.com

Medical Paradoxes in Clinic, Lab Should Encourage Physicians to Reappraise Ideas about Health and Disease

Simon M. Helfgott, MD  |  January 19, 2017

Wash your hands. This most basic tenet of proper hygiene has been drummed into our heads for years. It’s an obvious infection prevention activity, yet for years, compliance among physicians and other caregivers has been lackluster. To rectify this matter, regulatory agencies began auditing hospital staff adherence to this axiom of infection prevention. Not only…

Filed under:OpinionResearch RheumRheuminationsSpeak Out Rheum Tagged with:clinicDietDiseaseDrugslaboutcomeparadoxpatient careResearchrheumatologistrheumatologySmoking

A New Approach to Fracture Prevention

Susan Bernstein  |  December 14, 2016

Glucocorticoids are widely prescribed by rheumatologists, and the effects of daily and cumulative doses of these drugs on bone mineral density (BMD) are important elements of a draft clinical guideline document presented on Nov. 13 at the 2016 ACR/ARHP Annual Meeting in Washington, D.C. Leaders of the ACR guideline project discussed their recommendations at the…

Filed under:Clinical Criteria/GuidelinesConditionsMeeting ReportsOsteoarthritis and Bone DisordersProfessional Topics Tagged with:2016 ACR/ARHP Annual Meetingdraft clinical guidelinefracture risk factorsFracturesGlucocorticoid-Induced OsteoporosisGlucocorticoid-Induced Osteoporosis Prevention and Treatment: An Updated ACR Clinical GuidelineGlucocorticoidsOsteoporosis

Treating the Athlete: New Thoughts on How to Prevent & Treat Arthritis in Athletes & Raise Their Awareness

Karen Appold  |  November 4, 2016

All athletes—amateur and professional—should understand their risks for developing injury-related arthritis. Rheumatologists and other physicians at the Hospital for Special Surgery in New York take a rapid approach to treating athletes, often considering intense physical therapy, innovative treatments and surgery much sooner than for the average patient—all to keep joints healthy and enable athletes to play for as long as possible…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:Exercise/physical therapyinjuryphysical fitnessPhysical Therapysecukinumab

  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 23
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences